Evidence map›Paper›PMID 40134146›Full record

ReviewObesity (Silver Spring, Md.)2025

Regulation of the terminal complement cascade in adipose tissue for control of its volume, cellularity, and fibrosis.

Ilja L Kruglikov, Philipp E Scherer

Abstract readReview
In one paragraph

Review in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ilja L KruglikovScientific Department, Wellcomet GmbH, Karlsruhe, Germany.
Philipp E SchererTouchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0003-0680-3392

Funding

The role of AgRP/Auga-ALK pathway in FGF21's brain action on agingP01AG051459 · NIA · YALE UNIVERSITY · PI PHILIPP E SCHERER · 2016 to 2026
$25.7M
Adiponectin, A Protein Secreted From Adipose TissueR01DK055758 · NIDDK · YESHIVA UNIVERSITY · PI SCHERER, PHILIPP E · 2000 to 2024
$10.9M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeffrey M Zigman · 2022 to 2026
$7.4M
Generation of Novel Genetic Tools to Study Cellular Heterogeneity in Adipose TissuesRC2DK118620 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI GUPTA, RANA K, SCHERER, PHILIPP E · 2019 to 2023
$7.0M
White Adipose Tissue Physiology, Mitochondrial Function and AdiponectinR01DK099110 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI PHILIPP E SCHERER · 2013 to 2026
$6.7M
Metabolic Benefits of Leptin ReductionR01DK127274 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI JOEL K. ELMQUIST, PHILIPP E SCHERER · 2021 to 2026
$5.1M
Physiological Role of Dedifferentiating Dermal Adipose TissueR01DK131537 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI SCHERER, PHILIPP E · 2022 to 2025
$2.1M
NIA NIH HHS P01 AG051459NIA NIH HHS P01-AG051459NIDDK NIH HHS P30 DK127984NIDDK NIH HHS R01 DK055758NIDDK NIH HHS R01 DK099110NIDDK NIH HHS R01-DK099110NIDDK NIH HHS R01 DK127274NIDDK NIH HHS R01-DK127274NIDDK NIH HHS R01 DK131537NIDDK NIH HHS R01-DK131537NIDDK NIH HHS R01-DK55758NIDDK NIH HHS RC2 DK118620
6 · The paper itself

Abstract

White adipose tissue (WAT) is a reservoir for various pathogens and their products, such as lipopolysaccharides. Therefore, it must be equipped with a defense mechanism connected with the activation of innate immunity. This explains the phenomenon that adipocytes express components of the classical and alternative complement pathways, which can be activated even in the absence of opportunistic pathogens. Terminal stages of the complement pathway are related to the production of membrane attack complexes and, thus, can cause lysis of pathogens, as well as autolysis of host adipocytes, contributing to the regulation of the cellularity in WAT. Complement-induced autolysis of adipocytes is counteracted by a number of cellular defense mechanisms. This versatility of activation and suppression processes enables a broad range of adaptability to physiological contexts, ranging from the development of hypertrophic WAT to lipodystrophy. Pathogen-induced activation of the complement pathway in WAT also induces a profibrotic phenotype. These processes may also be involved in the regulation of insulin resistance in adipocytes. This explains the dual immune/metabolic role of the complement pathway in WAT: the pathway is an integral part of the immune response but also potently involved in the control of volume and cellularity of WAT under both physiological and pathological conditions.

Indexed as

Adipose Tissue, WhiteComplement ActivationComplement System ProteinsAdipocytesAnimalsFibrosisHumansImmunity, InnateInsulin ResistanceObesityComplement System Proteins

Identifiers

PMID40134146
PMCPMC12015659

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.